![Kevin Robert Pojasek](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Kevin Robert Pojasek
Director/Miembro de la Junta en Ervaxx Ltd. .
Cargos activos de Kevin Robert Pojasek
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Ervaxx Ltd.
![]() Ervaxx Ltd. Pharmaceuticals: MajorHealth Technology Ervaxx Ltd. is a British company that pioneers the use of dark antigens to deliver targeted immunotherapies for treating and preventing cancer. The company was founded in 2016 by George Kassiotis, Drew M. Pardoll and is based in London, UK. The company's powerful, proprietary edapt platform has been developed to discover and validate dark antigens providing an in-depth assessment of candidate antigens on primary tumor cells along with their immunogenic potential. Ervaxx is advancing a pipeline of T cell receptor-based therapies, off-the-shelf cancer vaccines, and other immunotherapies leveraging these insights into the role of dark antigens in cancer. | Director/Miembro de la Junta | 01/09/2018 | - |
Historial de carrera de Kevin Robert Pojasek
Estadísticas
Internacional
Reino Unido | 2 |
Operativa
Director/Board Member | 1 |
Sectorial
Health Technology | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 1 |
---|---|
Ervaxx Ltd.
![]() Ervaxx Ltd. Pharmaceuticals: MajorHealth Technology Ervaxx Ltd. is a British company that pioneers the use of dark antigens to deliver targeted immunotherapies for treating and preventing cancer. The company was founded in 2016 by George Kassiotis, Drew M. Pardoll and is based in London, UK. The company's powerful, proprietary edapt platform has been developed to discover and validate dark antigens providing an in-depth assessment of candidate antigens on primary tumor cells along with their immunogenic potential. Ervaxx is advancing a pipeline of T cell receptor-based therapies, off-the-shelf cancer vaccines, and other immunotherapies leveraging these insights into the role of dark antigens in cancer. | Health Technology |
- Bolsa de valores
- Insiders
- Kevin Robert Pojasek
- Experiencia